ERLOTIREL-100

About

Erlotinib is a potent, orally active tyrosine kinase inhibitor specifically designed for the treatment of certain advanced cancers, primarily non-small cell lung cancer (NSCLC) and pancreatic cancer. Its mechanism of action involves selectively blocking the epidermal growth factor receptor (EGFR), a protein often overexpressed or mutated in various solid tumors. By inhibiting EGFR signaling pathways, erlotinib effectively impedes cancer cell growth, proliferation, and survival. This targeted therapy is particularly beneficial for patients whose tumors harbor specific activating EGFR mutations, leading to significant improvements in progression-free survival and overall response rates. It represents a crucial option in personalized cancer medicine, offering a more precise approach to treatment compared to conventional chemotherapy. Regular monitoring for efficacy and side effects is essential during therapy.

Uses

• Non-small cell lung cancer (NSCLC)
• Pancreatic cancer
• EGFR mutation-positive NSCLC
• Maintenance therapy for NSCLC

Directions For Use

Take orally as directed by your physician, usually once daily on an empty stomach.

Benefits

• Targets specific cancer pathways
• Improved progression-free survival
• Oral administration convenience
• Effective in EGFR-mutated NSCLC
• May reduce tumor growth
• Potential for improved quality of life

Side Effects

• Rash (acneiform)
• Diarrhea
• Nausea
• Vomiting
• Fatigue
• Anorexia
• Dry skin
• Pruritus
• Stomatitis
• Conjunctivitis
• Interstitial lung disease (rare)
• Hepatotoxicity (rare)

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate liver side effects.
• Pregnancy - Not recommended during pregnancy due to potential fetal harm; use effective contraception.
• Breastfeeding - Avoid breastfeeding as the drug may pass into breast milk and harm the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustment may be necessary.
• Kidney - Use with caution in patients with renal impairment; dose adjustment may be necessary.
• Lung - Monitor for new or worsening pulmonary symptoms due to risk of interstitial lung disease.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.